Matthias Loehr - 31 Mar 2022 Form 3 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Director
Signature
/s/ Matthias Loehr
Issuer symbol
PMCB
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
3
Filing time
11 Apr 2022, 09:00:20 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMCB Common Stock 3,004 31 Mar 2022 By BB Biomed Consulting GMBH F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021.